Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26241918 | 0.82 | OPRM1 (0.44) | SMN1; SMN2DRD2DRD4 | |
| SCHEMBL20009032 | 0.80 | SLC6A7 (0.38) | HRH3KDM4EDRD2DRD4 | |
| SCHEMBL20012576 | 0.79 | GRIN2B (0.40) | DRD2DRD4PLD1 | |
| SCHEMBL20009044 | 0.78 | KDM4E (0.37) | KDM4ESMN1; SMN2 | |
| SCHEMBL9963415 | 0.76 | IDH1 (0.41) | HRH3KDM4EHSD17B10 | |
| SCHEMBL9963414 | 0.76 | IDH1 (0.41) | HRH3KDM4EHSD17B10 | |
| SCHEMBL20009007 | 0.76 | HRH3 (0.46) | HRH3DRD4 | |
| SCHEMBL30124446 | 0.75 | HRH3 (0.46) | HRH3KDM4EHSD17B10DRD2DRD4 | |
| SCHEMBL20008965 | 0.75 | OPRM1 (0.47) | HRH3DRD2DRD4 | |
| SCHEMBL9963410 | 0.75 | OPRM1 (0.44) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | HRH3 203/4885KDM4E 1623/4885HSD17B10 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.